Sunitinib. For some gastrointestinal stromal tumours

Prescrire International

Volumn 16, Issue 90, 2007, Pages 138-141

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; IMATINIB; INTERLEUKIN 2; KETOCONAZOLE; PLACEBO; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANEMIA; ANOREXIA; ARTICLE; BLOOD CLOTTING DISORDER; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FATIGUE; FETUS MALFORMATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; HAIR; HAIR DISCOLORATION; HAIR LOSS; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CANCER; LEUKOPENIA; LUNG EMBOLISM; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QT PROLONGATION; SIDE EFFECT; SKIN DISEASE; STOMATITIS; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; THYROID DISEASE; TUMOR BLEEDING; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; KIDNEY TUMOR; METASTASIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPOTHYROIDISM; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES;

EID: 34547878025     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Prescrire Rédaction "Les tumeurs stromales du tube digestif" Rev Prescrire 2003; 23 (239): 379-380.
2. Prescrire Editorial Staff "Imatinib in gastrointestinal stromal tumours" Prescrire Int 2003; 12 (67): 163-164.
3. European Medicines Agency - CHMP "European Public Assessment Report - Sutent -Scientific discussion": 47 pages (rev. 1): 47 pages + 29 pages; posted on the EMEA website on 5 March 2007.
4. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number NDA 21-938 (GIST) NDA21-968 (MRCC) - Statistical Review" 5 January 2006: 32 pages.
5. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number NDA 21-938 (GIST) - Medical Review" 25 January 2006: 93 pages.
6. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number NDA21-968 (MRCC) - Medical Review" 17 January 2006: 105 pages.
7. Motzer RJ et al. "Sunitinib in patients with metastastic renal cell carcinoma" JAMA 2006; 295 (21): 2516-2524.
8. Motzer RJ et al. "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma" N Engl J Med 2007; 356 (2): 115-124.
9. Motzer RJ et al. "Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)" J Clin Oncol 2006; 24 (18 suppl.): abstr. LBA3.
10. Demetri GD et al. "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial" Lancet 2006; 368 (94): 1329-1338.
11. Joensuu H "Sunitinib for imatinib-resistant GIST" Lancet 2006; 368: 1303-1304.
12. European Commission "Summary of product characteristics-Sutent" 17 January 2007: 18 pages.
13. Desai J et al. "Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal rumors" Ann Intern Med 2006; 145 (9): 660-664.
14. European Medicines Agency "Press release. Meeting highlights from the Committee for medicinal products for human use" 16-18 October 2006 19 October 2006: 2 pages.